Editor’s Note: Morgan Scientific became Vitalograph on November 5, 2026, the natural next step following two years of strong growth since Vitalograph’s acquisition of Morgan Scientific in 2024. Throughout this interview, Gareth Morgan reflects on the growth, integration, and future vision that have shaped the evolution to a single Vitalograph brand.
In the highly specialized field of pulmonary diagnostics, the acquisition of Morgan Scientific by Vitalograph in 2024 marked the beginning of a broader transformation that ultimately led to the organization’s evolution into a single Vitalograph brand. More than a change in ownership, it united two companies with deep roots in respiratory diagnostics and created a uniquely integrated organization combining advanced software development, diagnostic technologies, manufacturing expertise, and clinical trial capabilities.
For Gareth Morgan, the acquisition was more than a business transaction. It represented an opportunity to take a company with a long legacy in pulmonary diagnostics and accelerate its growth through access to greater resources, expertise, and global reach.
The acquisition delivered immediate benefits, marking the beginning of an exciting new chapter for Morgan Scientific. Gareth Morgan, who led the company through the acquisition and subsequent integration, now serves as Executive Vice President of Vitalograph US. Gareth said the move would give Morgan Scientific a strong platform to build on its success and open up new opportunities for innovation and growth.
“And so, for Vitalograph to recognize Morgan Scientific’s value, and to invest so that it can continue to grow, has been fantastic,” said Gareth. “What impressed me most was that Vitalograph understood exactly what made Morgan Scientific successful in the first place. There was never any desire to change that. Instead, the goal was to invest in it, strengthen it, and combine it with Vitalograph’s own expertise in respiratory diagnostics. That’s what made this partnership so compelling.”
Few people have witnessed the evolution of pulmonary diagnostics as closely as Gareth Morgan. Having grown up in a family dedicated to respiratory diagnostics, he has seen firsthand how the industry has changed over the past several decades and where it may be headed next. As he describes it, “The profession is something that I was born into, really.”
From Respiratory Heritage to Global Innovation
The foundations of today’s comPAS™ pulmonary function testing ecosystem can be traced back to 1950, when the Morgan family’s involvement in respiratory diagnostics first began in the United Kingdom with Gareth’s grandfather, Phillip (PK). Decades later, Gareth’s father, Patrick, established Morgan Scientific in the United States, focusing on software solutions for pulmonary diagnostics.
That focus on innovation led to the launch of comPAS Software in 2000 and comPAS2 Software in 2020, technologies that helped transform workflow, integration, and configurability for pulmonary function testing. Today, those software capabilities form a key part of Vitalograph’s PFT solutions portfolio.
Meanwhile, in 1963, Vitalograph was founded in the UK and went on to become a global leader in respiratory diagnostics and clinical trial solutions. With more than 60 years of respiratory expertise, the company now supports healthcare professionals, researchers, and pharmaceutical organizations worldwide through innovative diagnostic technologies and services.
From Partnership to Acquisition
The relationship between Vitalograph and Morgan Scientific began long before the acquisition, with both companies working closely together and combining their respective strengths in respiratory diagnostics and software development. The result, Gareth says, is clear: “Folding these strengths together created what is, in my opinion, the top PFT ecosystem in the industry.”
In September 2024, Vitalograph cemented the alliance by acquiring Morgan Scientific. Looking back, Gareth says the acquisition allowed both organizations to build on what they already did well. Over the following two years, teams, technologies, and expertise came together naturally, expanding capabilities while creating new opportunities for employees and customers alike. This culminated in the decision to unite under a single Vitalograph brand, bringing everything together under a single Vitalograph name while retaining the people, products, and expertise customers had come to rely on. Gareth says customers now benefit from access to broader respiratory expertise, increased investment, expanded resources, and one of the industry’s most comprehensive respiratory diagnostic portfolios.
The growth speaks for itself: yearly US sales of Vitalograph’s PFT solutions have nearly doubled since 2024.
This investment immediately materialized into personnel and infrastructure:
- Rapid Personnel Expansion: The US team has more than doubled in size since the acquisition, all over the business, including support, sales, implementation, and management.
- Infrastructure Investment: Vitalograph has invested in IT, marketing, HR and finance to support the growing business.
The transition also involved a significant shift in leadership and strategy, with Gareth helping lead the integration process and shaping the future direction of the unified organization.
“I feel incredibly lucky. The company leaders, CEO Frank Keane, Gary Lancaster (Chief Commercial Officer), and Helen Venn (Chief Science & Strategy Officer and granddaughter of the founders of Vitalograph), gave me a tremendous opportunity to create not just my vision, but a collective view of what the business could become. And we’ve been enacting that plan for the last two years.”
“What really impressed me was the depth of respiratory expertise across the Vitalograph organization,” Gareth says. “Whether it’s diagnostics, clinical trials, product development, or customer support, there are people across Vitalograph who have spent decades dedicated to respiratory health. That’s a powerful thing to be part of.”
Unifying Culture and Raising the Bar
The primary goal post-acquisition has been to create a unified team and culture by combining the best practices of both companies—Vitalograph’s Kansas City office and Morgan Scientific’s Haverhill office—with the intent of “creating something greater than the sum of its parts,” Gareth says.
Integrating two large teams, each with established cultures and standard operating procedures, naturally presented challenges. Yet, Gareth believes the strongest qualities of each entity are prevailing. “What I really see is the best of both companies emerging and rising to the top,” he said, adding: “The tide has been steadily rising since the acquisition. And so that floats all boats. It brings everyone up.”
Crucially, he says this transformative period was navigated successfully without detrimental staff losses. The emphasis has been “very much about the people,” with investment in management training to ensure personnel are “looked after, supported and developed.” This reflects the people-centric culture that has guided both organizations throughout the integration process. According to Gareth, maintaining continuity for employees and customers while bringing the strengths of both companies together has been central to the evolution toward a unified Vitalograph organization.
The Continuum of Solutions: A Unique Market Offering
Now two years into the joint company’s journey, Gareth says the combined capabilities of Vitalograph’s manufacturing prowess and the integration of Morgan Scientific’s advanced software into Vitalograph’s core product development roadmap have created a distinct competitive advantage through its vertical integration, delivering what he calls a “continuum of solutions.”
This continuum means the business designs, develops, and manufactures products across the full spectrum of respiratory diagnostics, from bacterial/viral filters and peak flow meters, up through screeners, monitors, standalone devices, and PC-based systems, reaching the most sophisticated equipment, including gas analyzers, plethysmographs and cardiopulmonary exercise testing (CPET) equipment.
The PFT product line is unified through the comPAS2 software, which brings together a range of advanced PFT, spirometry, and complementary diagnostics, all interconnected through an innovative and fully configurable software platform to provide a high-performing and seamless pulmonary assessment experience. “The comPAS software acts as a strong thread that is woven all the way through Vitalograph’s PFT offering, managing complexity from respiratory screening to catch lung disease early, to the most advanced pulmonary function testing,” he says.
This comprehensive product portfolio allows the company to meet the needs of a patient or an end user at any point along the journey of respiratory diagnostics. “This is considered unique in our industry, providing customers with the flexibility to scale up or down the continuum as their needs evolve,” Gareth says.
Gareth believes the move to a single Vitalograph identity makes it easier for customers to understand the full breadth of available solutions. Rather than navigating multiple brands, customers can access a unified respiratory diagnostics partner with expertise spanning routine spirometry, lung diffusion, lung volumes via plethysmography or gas dilution, respiratory monitoring, EMR-integrated software solutions, and clinical trial services.
“And so, when a customer comes to Vitalograph, they know we are not only going to be able to offer them a specific solution to meet their particular needs, but we have the flexibility to meet their needs at every stage of respiratory care.”
Advancing Respiratory Care Beyond the PFT Lab
While respiratory diagnostics remains central to Vitalograph’s mission, Gareth believes the company’s clinical trial expertise offers a unique perspective on the future of respiratory care.
“For more than two decades, Vitalograph has worked with pharmaceutical companies developing new respiratory therapies,” he explains. “Every day we’re helping clinicians make informed decisions about patient care while also supporting the development of the next generation of treatments. Few organizations have visibility across both sides of that journey.”
That experience, Gareth says, influences how Vitalograph approaches innovation across its portfolio, from pulmonary function testing and digital health technologies to the development of new respiratory solutions.
“As one Vitalograph, we’re able to bring together expertise from respiratory diagnostics, clinical research, software development, and digital health technologies in a way that’s genuinely unique within our industry.”
Future Readiness: Ai, Digital Health, and Education
Looking ahead, Gareth sees the combination of respiratory diagnostics, clinical trial expertise, digital health technologies, and artificial intelligence as creating significant opportunities to improve both clinical care and respiratory research.
“I think that pulmonary diagnostics will look very different in 20 years, but even as short as 10 years,” he says. A major driver of this change is the rapid acceleration of artificial intelligence. “The increase of Ai use in every industry is accelerating product development timelines,” he added, forecasting that primary diagnostics will look very different in the years ahead.
In parallel, Vitalograph is developing digital health technologies that connect with patients beyond the PFT lab and into the home, supporting earlier identification and intervention. “…just as an insulin pump can alert a patient that their glucose levels are off and even stream data back to a patient’s physician, respiratory monitors used by patients at home will help alert a patient of an impending exacerbation or suggest a change to their medication,” Gareth reflects. “It’s already happening today to some extent, but better solutions are needed to make their use more widespread and consistent, and that’s where Vitalograph’s digital health technologies come in.”
Education remains another key area of investment. Vitalograph has significantly expanded its learning management platform, providing customers with comprehensive training both remotely and in person.
That commitment extends to the wider respiratory community. In 2025, Vitalograph was chosen as the official sponsor for the American Association for Respiratory Care’s Pulmonary Function Test (PFT) Guide, helping expand access to practical educational resources that support professional development in respiratory care.
As a global organization, Vitalograph also hosts key opinion leaders at the annual Future Readiness: Respiratory Diagnostics Summit in the UK, bringing together experts for discussion, debate, and education focused on the future of respiratory diagnostics.
Ultimately, Gareth sees the evolution from Morgan Scientific to Vitalograph as a natural reflection of what the organization has already become: a unified global respiratory diagnostics company built on decades of expertise, continued investment, and a shared commitment to improving lung health.
“Our future is less about what specific products we’ll be working on,” Gareth says, “and more about our mentality of not sitting still and thinking about how we can meet future challenges.”
Reflecting on the last two years, Gareth views the move to Vitalograph as the next chapter in Morgan Scientific’s evolution. By bringing together expertise in respiratory diagnostics, software development, and clinical trial solutions, Vitalograph has built a stronger foundation for future innovation.
For Gareth, the move to Vitalograph reflects not just where the company has been, but where it is going. Building on decades of respiratory expertise, he believes the organization is better positioned than ever to support healthcare professionals, advance research, and help shape the future of respiratory care.
RT
For more information, contact [email protected].
This article is sponsored by Vitalograph.
